Skip to main content

COVID-19 Topic Center

News

News
According to study findings published online in Cancer Chemotherapy and Pharmacology, researchers identified the optimal dose of selinexor in patients with diffuse large B-cell.
News
According to a cross-sectional study, patients with non-radiographic axial spondyloarthritis at moderate risk of cardiovascular disease per the Systematic COronary Risk Evaluation (SCORE) model were reclassified as very high risk after ultrasound imaging revealed carotid plaques.
News
For the treatment of moderate-to-severe atopic dermatitis, biologics with the most robust efficacy and safety evidence are dupilumab, baricitinib, abrocitinib, and delgocitinib, according to a systematic review.
News
Many officials are concerned that Blue Shield's take over of the vaccination program will cause health care workers to waste valuable time learning new data systems and software instead of tracking down the state's most vulnerable vaccine-eligible residents.
News
“Costs likely vary substantially between institutions and practices, but our data suggest that even with an efficient, dedicated prior authorization group, costs are high,” researchers wrote.
News
An analysis of the characteristics of 308 adults with moderate-to-severe atopic dermatitis starting or switching systematic therapy provides a real-world picture of the substantial burden of the disease, observed researchers in the Journal of Dermatological Treatment.
News
According to study findings, neurologic toxicities from treatment for relapsed or refractory diffuse large B-cell lymphoma increased total health care costs more than $70,000 on average for US patients.
News
For patients with generalized pustular psoriasis and palmoplantar pustulosis, health care resource utilization was high, findings showed.
News
More than 40% of US patients with atopic dermatitis or their caregivers say they spend $1000 or more out of pocket annually to manage the condition, according to study findings.
News
Conducted by researchers from RTI Health Solutions and Georgetown University, the analysis considered the cost-effectiveness and budget impact of using ibalizumab, a first-in-class, long-acting, postattachment HIV-1 inhibitor, in the difficult-to-treat population.
Back to Top